About Kineta
Kineta is a company based in Seattle (United States) founded in 2008 was acquired by TuHURA Biosciences in February 2025.. Kineta has raised $103.53 million across 35 funding rounds from investors including HHS, TuHURA Biosciences and Cheongbo Industrial. The company has 12 employees as of December 31, 2022. Kineta offers products and services including KVA12123 and CD27. Kineta operates in a competitive market with competitors including Emergent BioSolutions, Adjuvance Technologies, Eikonoklastes, EyeGene and Quratis, among others.
- Headquarter Seattle, United States
- Employees 12 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Kineta Inc.
-
Annual Revenue
$442 K-77as on Feb 28, 2023
-
Net Profit
$-17.13 M-22as on Feb 28, 2024
-
EBITDA
$-13.53 M14as on Feb 28, 2024
-
Total Equity Funding
$103.53 M (USD)
in 35 rounds
-
Latest Funding Round
$17.4 M (USD), Series D
Jun 13, 2022
-
Investors
HHS
& 6 more
-
Employee Count
12
as on Dec 31, 2022
-
Acquired by
TuHURA Biosciences
(Feb 06, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kineta
Kineta offers a comprehensive portfolio of products and services, including KVA12123 and CD27. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Blocks VISTA protein to enhance immune response against cancer.
Targets CD27 for improved cancer immune system activation.
Unlock access to complete
Unlock access to complete
Funding Insights of Kineta
Kineta has successfully raised a total of $103.53M across 35 strategic funding rounds. The most recent funding activity was a Series D round of $17.4 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 35
- Last Round Series D — $17.4M
-
First Round
First Round
(05 Sep 2008)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2022 | Amount | Series D - Kineta | Valuation |
investors |
|
| Feb, 2022 | Amount | Series D - Kineta | Valuation |
investors |
|
| Jul, 2021 | Amount | Series D - Kineta | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Kineta
Kineta has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, TuHURA Biosciences and Cheongbo Industrial. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Major auto components are manufactured and supplied to aftermarket.
|
Founded Year | Domain | Location | |
|
Wellcome is a global charitable foundation focused on health research.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Kineta
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Kineta
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kineta Comparisons
Competitors of Kineta
Kineta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Emergent BioSolutions, Adjuvance Technologies, Eikonoklastes, EyeGene and Quratis, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vaccines for viral infections are developed by the company.
|
|
| domain | founded_year | HQ Location |
Vaccine adjuvants are designed and manufactured for medical applications.
|
|
| domain | founded_year | HQ Location |
Tissue factor targeting therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Immune vaccines and diagnostics for ocular diseases are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines and cell therapies for tuberculosis are developed by Quratis.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Kineta
Frequently Asked Questions about Kineta
When was Kineta founded?
Kineta was founded in 2008.
Where is Kineta located?
Kineta is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Is Kineta a funded company?
Kineta is a funded company, having raised a total of $103.53M across 35 funding rounds to date. The company's 1st funding round was a Series D of $1.18M, raised on Sep 05, 2008.
How many employees does Kineta have?
As of Dec 31, 2022, the latest employee count at Kineta is 12.
What is the annual revenue of Kineta?
Annual revenue of Kineta is $442K as on Feb 28, 2023.
What does Kineta do?
Kineta is focused on developing immune-modulating therapeutics and vaccine adjuvants for autoimmune and infectious diseases. Autoimmune disease pipeline includes dalazitide in clinical trial phase 1B for Lupus, Psoriasis, Psoriatic Arthritis, RA, MS, Vasculitis, IBD, Asthma, AD, Type 1 diabetes (T1D). Antiviral pipeline includes compounds of preclinical categories innate-immune antivirals, vaccine adjuvants and direct-acting antivirals all of which discovered using its proprietary aviid antiviral discovery platform. It also has a chronic pain candidate in preclinical stage for diabetic nephropathy and traumatic injury.
Who are the top competitors of Kineta?
Kineta's top competitors include Adjuvance Technologies, Emergent BioSolutions and EyeGene.
What products or services does Kineta offer?
Kineta offers KVA12123 and CD27.
Who are Kineta's investors?
Kineta has 7 investors. Key investors include HHS, TuHURA Biosciences, Cheongbo Industrial, Wellcome, and NIAID.